About InSphero
InSphero is a company based in Schlieren (Switzerland) founded in 2009. InSphero has raised $35.02 million across 10 funding rounds from investors including ZEISS, Zurcher Kantonalbank and European Union. InSphero has completed 1 acquisition, including PhenoVista. InSphero offers products and services including Akura Microplate Technology, Akura Organ-on-Chip Technology, and 3D InSight Liver Microtissues. InSphero operates in a competitive market with competitors including Newcells Biotech, Pandorum, Vivodyne, NextVivo and Adapsyn, among others.
- Headquarter Schlieren, Switzerland
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$35.02 M (USD)
in 10 rounds
-
Latest Funding Round
Not available
-
Investors
ZEISS
& 7 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InSphero
InSphero offers a comprehensive portfolio of products and services, including Akura Microplate Technology, Akura Organ-on-Chip Technology, and 3D InSight Liver Microtissues.
Enables automated 3D cell culture for drug screening
Simulates human organs for advanced drug testing
Provides 3D liver models for toxicity and safety assessments
People of InSphero
Unlock access to complete
Funding Insights of InSphero
InSphero has successfully raised a total of $35.02M across 10 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InSphero
InSphero has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include ZEISS, Zurcher Kantonalbank and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Startup acceleration programs are operated across sectors to support growth.
|
Locked | Locked | Locked | |
|
Early-stage investments are directed toward ICT and health tech startups.
|
Locked | Locked | Locked |
Investor details for InSphero
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InSphero
InSphero has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include PhenoVista.
Investment portfolio details for InSphero
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
A CRO that provides phenotypic assay development and screening services.
|
Locked | Locked | 2014 | Locked |
Complete acquisition details for InSphero
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - InSphero
Detailed financials for InSphero
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Insphero Comparisons
Peer comparison for InSphero
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InSphero
InSphero operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Newcells Biotech, Pandorum, Vivodyne, NextVivo and Adapsyn, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Induced pluripotent stem cell-derived organoid models are developed for research.
|
|
| Locked | Locked | Locked |
Regenerative medicine and 3D tissues are developed for therapeutic uses.
|
|
| Locked | Locked | Locked |
Developer of AI-based platform for lab-grown human tissues
|
|
| Locked | Locked | Locked |
Immune-competent human-derived models are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Provider of computational tools for bacterial metabolomic and genomic data analysis
|
Detailed competitors of InSphero
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Insphero
Complete news archive for InSphero
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InSphero
InSphero was founded in 2009.
InSphero is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
InSphero is a funded company, having raised a total of $35.02M across 10 funding rounds to date.
InSphero was founded in 2009 in Schlieren, Switzerland, within the biotechnology sector. Organotypic 3D microtissues are produced for applications in biochemical compound screening and predictive drug testing. Services encompass compound toxicity testing, cell invasion assays, and interactions involving cells and extracellular matrices. Focus areas include metabolic diseases, oncology, and liver diseases, with offerings such as human prostate and mammary carcinoma, alongside rat liver microtissues.
InSphero's top competitors include Newcells Biotech, Vivodyne and Parallel Bio.
InSphero offers Akura Microplate Technology, Akura Organ-on-Chip Technology, and 3D InSight Liver Microtissues.
InSphero has made 1 acquisition, including PhenoVista.
InSphero has 8 investors. Key investors include ZEISS, Zurcher Kantonalbank, European Union, EIC Fund, and Jürg Gysi.